Tobalief
Natural health product licensed in Canada
- Licence holder
- Naturo Aid Pharmaceutical Inc.
- NPN or DIN-HM
- 80072429
- Status
- Active licence
- Licence date
- 8 September 2016
- Revision date
- 16 January 2026
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| (1R,5S)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido-[1,2-alpha][1,5]diazocin-8-one Source : Cystéine | 1.5 milligramme | Not calculated |
Non-medicinal ingredients
Dioxyde de silicium, Cellulose microcristalline, Hypromellose, L-Leucine, Pullulane, Palmitate d'ascorbyle
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | minimum: 2 Tous les jours ; maximum: 6 Tous les jours |
Uses authorised in Canada
Smoking cessation aid.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Some people may experience changes in both taste and appetite, dryness in the mouth, headache, irritability, nausea, constipation, tachycardia, light elevation of the arterial pressure.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you have hyperthyroidism. Consult a health care practitioner prior to use if you have an ulcer, ischemic heart disease, cardiac impairment, cerebrovascular disease, high blood pressure, renal or hepatic insufficiency. Consult a health care practitioner prior to use if you have diabetes mellitus. Keep out of reach of children. Symptoms of an overdose include nausea, abdominal pain, vomiting, diarrhea, cold sweat, dizziness, disturbed hearing and vision, mental confusion, rapid heartbeat, difficulty breathing and marked weakness. If you have a history of psychiatric disorders or if you experience psychological distress, consult your health care practitioner. May cause sleep disorders.
- Contre-indications
Do not use if you have arterial hypertension and advanced atherosclerosis. Do not use if you are pregnant or breastfeeding. Simultaneous administration of cytisine and smoking could lead to nicotine intoxication.
Source
Official Health Canada record, licence 80072429
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.